<p>Kestra Medical Technologies, Ltd.（纳斯达克股票代码：KMTS - 获取免费报告）的股票在目前覆盖该公司的五家评级机构中获得了 “持有” 的共识评级，Marketbeat 报道称。一位投资分析师给予该股票卖出评级，一位给予持有评级，三位给予买入评级。在过去一年中，更新了对该股票覆盖的分析师的平均一年目标价为 27.40 美元。</p>
<p>多家券商对 KMTS 进行了评论。高盛集团在 4 月 9 日的报告中将 Kestra Medical Technologies 的目标价从 22.00 美元下调至 17.00 美元，并对该股票设定了 “中性” 评级。BTIG Research 在 4 月 7 日的报告中重申了对 Kestra Medical Technologies 的 “买入” 评级，并设定了 32.00 美元的目标价。最后，Weiss Ratings 在 3 月 23 日的报告中重申了对 Kestra Medical Technologies 的 “卖出（d-）” 评级。</p>
<p><strong>阅读我们关于 KMTS 的最新股票报告</strong></p>
<h2>Kestra Medical Technologies 的内部买卖情况</h2>
<p>在其他新闻中，内部人士 Brian Daniel Webster 于 4 月 15 日星期三出售了该公司 15,000 股股票。该股票以平均价格 20.04 美元出售，总交易额为 300,600.00 美元。出售完成后，该内部人士直接持有该公司 349,786 股股票，估值约为 7,009,711.44 美元。这代表其持股比例下降了 4.11%。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，相关文件可通过此超链接访问。在过去的九十天里，内部人士出售了价值 988,650 美元的 45,000 股公司股票。公司内部人士持有该公司股票的 3.60%。</p>
<h2>Kestra Medical Technologies 的机构交易情况</h2>
<p>机构投资者最近调整了对该股票的持有情况。Mirae Asset Global Investments Co. Ltd. 在第三季度购买了价值 562,000 美元的 Kestra Medical Technologies 新股份。Jennison Associates LLC 在第四季度将其在 Kestra Medical Technologies 的持股比例提高了 15.0%。Jennison Associates LLC 现在拥有 219,355 股该公司的股票，估值为 5,817,000 美元，此前在此期间又购买了 28,573 股。TD Asset Management Inc 在第三季度将其在 Kestra Medical Technologies 的持股比例提高了 17.3%。TD Asset Management Inc 现在拥有 92,306 股该公司的股票，估值为 2,193,000 美元，此前在此期间又购买了 13,588 股。China Universal Asset Management Co. Ltd. 在第三季度购买了价值 48,000 美元的 Kestra Medical Technologies 新股份。最后，Russell Investments Group Ltd. 在第四季度将其在 Kestra Medical Technologies 的持股比例提高了 43.5%。Russell Investments Group Ltd. 现在拥有 1,563 股该公司的股票，价值 41,000 美元，此前在上个季度又购买了 474 股。</p>
<h2>Kestra Medical Technologies 股票表现</h2>
<p>纳斯达克 KMTS 的股票在星期二开盘价为 20.55 美元。该公司的债务与股本比率为 0.15，流动比率为 7.32，速动比率为 7.32。该股票的 50 日移动平均价格为 21.34 美元，200 日移动平均价格为 24.20 美元。Kestra Medical Technologies 的一年低点为 13.25 美元，一年高点为 30.00 美元。该公司的市值为 12 亿美元，市盈率为-5.19，贝塔值为 0.82。</p>
<p>Kestra Medical Technologies（纳斯达克股票代码：KMTS - 获取免费报告）最近于 3 月 17 日星期二发布了季度财报。该公司报告季度每股收益（EPS）为（0.61）美元，低于分析师的共识预期（0.60）美元，差额为（0.01）美元。Kestra Medical Technologies 的净利润率为-171.87%，股本回报率为-65.49%。该公司在本季度的收入为 2455 万美元。与去年同期相比，该公司的季度收入增长了 62.7%。分析师平均预测，Kestra Medical Technologies 在当前年度将发布-2.34 美元的每股收益。</p>
<h2>关于 Kestra Medical Technologies</h2>
<p>（获取免费报告）</p>
<p>我们是一家商业阶段的可穿戴医疗设备和数字医疗公司，专注于通过直观、智能和互联的监测和治疗干预技术来改善心血管疾病患者的结果。我们开发并商业化了我们的心脏恢复系统平台，这是一个综合且先进的系统，将监测、治疗、数字健康和患者支持服务整合为一个统一的解决方案。我们心脏恢复系统平台的基石是 ASSURE WCD，这是一种下一代可穿戴心脏复律除颤器（“WCD”），用于保护面临突发心脏骤停（“SCA”）风险的患者，这是一项重大公共卫生问题，约占美国所有心血管死亡的 50%。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，超过 Kestra Medical Technologies</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S01UUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S01UUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kestra Medical Technologies 吗？</h2>
<p>在考虑投资 Kestra Medical Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Kestra Medical Technologies 并不在名单上。</p>
<p>虽然 Kestra Medical Technologies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KMTS

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Kestra Medical Technologies, Ltd.（纳斯达克代码：KMTS）获得了五家券商的 “持有” 共识评级。分析师们给出了一个卖出、一个持有和三个买入评级，平均目标价为 27.40 美元。高盛将其目标价从 22.00 美元下调至 17.00 美元，而 BTIG Research 维持买入评级，目标价为 32.00 美元。内部人士 Brian Daniel Webster 出售了 15,000 股，减少了 4.11% 的持股比例。该股票开盘价为 20.55 美元，市值为 12 亿美元，上一季度的每股收益为负 0.61 美元</p>

<p>Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus rating of &#34;Hold&#34; from the five ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $27.40.</p>
<div class="lb-trans"><p>Kestra Medical Technologies, Ltd.（纳斯达克股票代码：KMTS - 获取免费报告）的股票在目前覆盖该公司的五家评级机构中获得了 “持有” 的共识评级，Marketbeat 报道称。一位投资分析师给予该股票卖出评级，一位给予持有评级，三位给予买入评级。在过去一年中，更新了对该股票覆盖的分析师的平均一年目标价为 27.40 美元。</p>
</div><p>A number of brokerages have commented on KMTS. The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, April 9th. BTIG Research reaffirmed a &#34;buy&#34; rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd.</p>
<div class="lb-trans"><p>多家券商对 KMTS 进行了评论。高盛集团在 4 月 9 日的报告中将 Kestra Medical Technologies 的目标价从 22.00 美元下调至 17.00 美元，并对该股票设定了 “中性” 评级。BTIG Research 在 4 月 7 日的报告中重申了对 Kestra Medical Technologies 的 “买入” 评级，并设定了 32.00 美元的目标价。最后，Weiss Ratings 在 3 月 23 日的报告中重申了对 Kestra Medical Technologies 的 “卖出（d-）” 评级。</p>
</div><p><strong>Read Our Latest Stock Report on KMTS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 KMTS 的最新股票报告</strong></p>
</div><h2>Insider Buying and Selling at Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 的内部买卖情况</h2>
</div><p>In other news, insider Brian Daniel Webster sold 15,000 shares of the company's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $20.04, for a total transaction of $300,600.00. Following the completion of the sale, the insider directly owned 349,786 shares in the company, valued at approximately $7,009,711.44. This represents a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 45,000 shares of company stock worth $988,650. Corporate insiders own 3.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Brian Daniel Webster 于 4 月 15 日星期三出售了该公司 15,000 股股票。该股票以平均价格 20.04 美元出售，总交易额为 300,600.00 美元。出售完成后，该内部人士直接持有该公司 349,786 股股票，估值约为 7,009,711.44 美元。这代表其持股比例下降了 4.11%。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，相关文件可通过此超链接访问。在过去的九十天里，内部人士出售了价值 988,650 美元的 45,000 股公司股票。公司内部人士持有该公司股票的 3.60%。</p>
</div><h2>Institutional Trading of Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 的机构交易情况</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter valued at $562,000. Jennison Associates LLC lifted its position in shares of Kestra Medical Technologies by 15.0% during the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company's stock valued at $5,817,000 after acquiring an additional 28,573 shares during the period. TD Asset Management Inc lifted its position in shares of Kestra Medical Technologies by 17.3% during the 3rd quarter. TD Asset Management Inc now owns 92,306 shares of the company's stock valued at $2,193,000 after acquiring an additional 13,588 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter valued at $48,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after buying an additional 474 shares during the last quarter.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有情况。Mirae Asset Global Investments Co. Ltd. 在第三季度购买了价值 562,000 美元的 Kestra Medical Technologies 新股份。Jennison Associates LLC 在第四季度将其在 Kestra Medical Technologies 的持股比例提高了 15.0%。Jennison Associates LLC 现在拥有 219,355 股该公司的股票，估值为 5,817,000 美元，此前在此期间又购买了 28,573 股。TD Asset Management Inc 在第三季度将其在 Kestra Medical Technologies 的持股比例提高了 17.3%。TD Asset Management Inc 现在拥有 92,306 股该公司的股票，估值为 2,193,000 美元，此前在此期间又购买了 13,588 股。China Universal Asset Management Co. Ltd. 在第三季度购买了价值 48,000 美元的 Kestra Medical Technologies 新股份。最后，Russell Investments Group Ltd. 在第四季度将其在 Kestra Medical Technologies 的持股比例提高了 43.5%。Russell Investments Group Ltd. 现在拥有 1,563 股该公司的股票，价值 41,000 美元，此前在上个季度又购买了 474 股。</p>
</div><h2>Kestra Medical Technologies Stock Performance</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 股票表现</h2>
</div><p>Shares of NASDAQ KMTS opened at $20.55 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The stock's fifty day moving average price is $21.34 and its two-hundred day moving average price is $24.20. Kestra Medical Technologies has a one year low of $13.25 and a one year high of $30.00. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -5.19 and a beta of 0.82.</p>
<div class="lb-trans"><p>纳斯达克 KMTS 的股票在星期二开盘价为 20.55 美元。该公司的债务与股本比率为 0.15，流动比率为 7.32，速动比率为 7.32。该股票的 50 日移动平均价格为 21.34 美元，200 日移动平均价格为 24.20 美元。Kestra Medical Technologies 的一年低点为 13.25 美元，一年高点为 30.00 美元。该公司的市值为 12 亿美元，市盈率为-5.19，贝塔值为 0.82。</p>
</div><p>Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million during the quarter. The company's revenue for the quarter was up 62.7% compared to the same quarter last year. On average, equities analysts forecast that Kestra Medical Technologies will post -2.34 EPS for the current year.</p>
<div class="lb-trans"><p>Kestra Medical Technologies（纳斯达克股票代码：KMTS - 获取免费报告）最近于 3 月 17 日星期二发布了季度财报。该公司报告季度每股收益（EPS）为（0.61）美元，低于分析师的共识预期（0.60）美元，差额为（0.01）美元。Kestra Medical Technologies 的净利润率为-171.87%，股本回报率为-65.49%。该公司在本季度的收入为 2455 万美元。与去年同期相比，该公司的季度收入增长了 62.7%。分析师平均预测，Kestra Medical Technologies 在当前年度将发布-2.34 美元的每股收益。</p>
</div><h2>About Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>关于 Kestra Medical Technologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.</p>
<div class="lb-trans"><p>我们是一家商业阶段的可穿戴医疗设备和数字医疗公司，专注于通过直观、智能和互联的监测和治疗干预技术来改善心血管疾病患者的结果。我们开发并商业化了我们的心脏恢复系统平台，这是一个综合且先进的系统，将监测、治疗、数字健康和患者支持服务整合为一个统一的解决方案。我们心脏恢复系统平台的基石是 ASSURE WCD，这是一种下一代可穿戴心脏复律除颤器（“WCD”），用于保护面临突发心脏骤停（“SCA”）风险的患者，这是一项重大公共卫生问题，约占美国所有心血管死亡的 50%。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Kestra Medical Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，超过 Kestra Medical Technologies</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S01UUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=KMTS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kestra Medical Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kestra Medical Technologies 吗？</h2>
</div><p>Before you consider Kestra Medical Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Kestra Medical Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Kestra Medical Technologies 并不在名单上。</p>
</div><p>While Kestra Medical Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kestra Medical Technologies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kestra Medical Technologies, Ltd.（纳斯达克股票代码：KMTS）被券商给予 “持有” 评级的平均评价